Manning & Napier Advisors LLC Trims Position in Gilead Sciences, Inc. $GILD

Manning & Napier Advisors LLC decreased its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 5.2% during the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 103,065 shares of the biopharmaceutical company’s stock after selling 5,606 shares during the quarter. Manning & Napier Advisors LLC’s holdings in Gilead Sciences were worth $14,364,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also made changes to their positions in the business. Strategic Investment Solutions Inc. IL acquired a new stake in Gilead Sciences in the 4th quarter worth about $25,000. Vermillion & White Wealth Management Group LLC lifted its holdings in shares of Gilead Sciences by 71.4% during the 4th quarter. Vermillion & White Wealth Management Group LLC now owns 204 shares of the biopharmaceutical company’s stock worth $25,000 after acquiring an additional 85 shares during the period. Quattro Advisors LLC acquired a new stake in shares of Gilead Sciences in the fourth quarter worth approximately $26,000. Wealth Preservation Advisors LLC boosted its position in shares of Gilead Sciences by 60.0% in the fourth quarter. Wealth Preservation Advisors LLC now owns 216 shares of the biopharmaceutical company’s stock worth $27,000 after acquiring an additional 81 shares during the last quarter. Finally, Ares Financial Consulting LLC purchased a new stake in Gilead Sciences in the fourth quarter valued at approximately $28,000. Hedge funds and other institutional investors own 83.67% of the company’s stock.

Gilead Sciences Stock Down 3.7%

Shares of GILD traded down $5.01 during midday trading on Friday, reaching $129.83. 5,934,235 shares of the company were exchanged, compared to its average volume of 7,886,756. The stock has a 50-day moving average price of $129.78 and a 200-day moving average price of $134.96. The company has a market cap of $161.19 billion, a price-to-earnings ratio of 17.69 and a beta of 0.32. Gilead Sciences, Inc. has a 1-year low of $107.75 and a 1-year high of $157.29. The company has a current ratio of 1.97, a quick ratio of 1.77 and a debt-to-equity ratio of 0.89.

Gilead Sciences (NASDAQ:GILD) last posted its earnings results on Thursday, May 7th. The biopharmaceutical company reported $2.03 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.91 by $0.12. The business had revenue of $6.96 billion during the quarter, compared to analyst estimates of $6.91 billion. Gilead Sciences had a return on equity of 48.19% and a net margin of 30.99%.The company’s revenue for the quarter was up 4.4% compared to the same quarter last year. During the same quarter last year, the firm earned $1.81 earnings per share. Gilead Sciences has set its FY 2026 guidance at -1.050–0.650 EPS. Research analysts expect that Gilead Sciences, Inc. will post -0.8 earnings per share for the current year.

Gilead Sciences Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Monday, June 29th. Stockholders of record on Monday, June 15th were paid a dividend of $0.82 per share. The ex-dividend date was Monday, June 15th. This represents a $3.28 dividend on an annualized basis and a dividend yield of 2.5%. Gilead Sciences’s dividend payout ratio (DPR) is currently 44.69%.

Insider Transactions at Gilead Sciences

In related news, insider Johanna Mercier sold 28,000 shares of Gilead Sciences stock in a transaction on Friday, May 15th. The shares were sold at an average price of $131.29, for a total transaction of $3,676,120.00. Following the sale, the insider owned 125,779 shares of the company’s stock, valued at $16,513,524.91. The trade was a 18.21% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Andrew D. Dickinson sold 3,000 shares of the business’s stock in a transaction on Monday, June 15th. The stock was sold at an average price of $125.40, for a total transaction of $376,200.00. Following the completion of the transaction, the chief financial officer owned 171,646 shares in the company, valued at $21,524,408.40. This represents a 1.72% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders have sold 83,000 shares of company stock valued at $10,824,500. Corporate insiders own 0.30% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts have weighed in on GILD shares. Weiss Ratings downgraded shares of Gilead Sciences from a “buy (b)” rating to a “buy (b-)” rating in a research note on Thursday, May 28th. Rothschild & Co Redburn cut their target price on Gilead Sciences from $170.00 to $167.00 in a research report on Monday, May 11th. Royal Bank Of Canada lowered their price target on Gilead Sciences from $122.00 to $120.00 and set a “sector perform” rating for the company in a research report on Tuesday. Leerink Partners dropped their price target on Gilead Sciences from $148.00 to $146.00 in a research note on Friday, May 8th. Finally, HSBC raised Gilead Sciences from a “hold” rating to a “buy” rating and lifted their price objective for the company from $133.00 to $155.00 in a research note on Monday, July 6th. Twenty-six equities research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, Gilead Sciences has an average rating of “Moderate Buy” and a consensus target price of $159.04.

About Gilead Sciences

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.